Ipamorelin

Ipamorelin is a synthetic pentapeptide — a short chain of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) — classified as a growth hormone secretagogue (GHS). It was first described in the late 1990s by researchers at Novo Nordisk as part of a search for compounds that could stimulate the body's own production of growth hormone (GH) without the broad hormonal side effects seen with earlier peptides.

Rather than introducing growth hormone directly into the body, Ipamorelin works upstream: it signals the pituitary gland to release the GH it already produces. This distinction matters because it means the hormone is released in a natural, pulsatile rhythm and remains subject to the body's normal regulatory checks. To understand where peptides like this fit in the broader landscape, our overview of what peptides are provides useful background.

Ipamorelin belongs to the same functional family as GHRP-2 and GHRP-6 (growth hormone-releasing peptides), but it was specifically engineered to be more selective. Its molecular weight is approximately 711.85 Daltons, and it is typically supplied as a lyophilized (freeze-dried) powder for reconstitution in research settings.

It is important to state at the outset that Ipamorelin has not been approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for human therapeutic use. The majority of available evidence comes from animal and early-phase studies. This article is for educational purposes only and is not medical advice; anyone considering peptide use should consult a qualified healthcare professional.

The single characteristic that most distinguishes Ipamorelin from its predecessors is its selectivity. In the foundational pharmacological work by Raun and colleagues (1998), Ipamorelin stimulated GH release with a potency comparable to GHRP-6, but — crucially — without the unwanted release of other pituitary hormones.

Older secretagogues such as GHRP-6 reliably raise GH, but they also tend to elevate cortisol, prolactin, and adrenocorticotropic hormone (ACTH). Chronic elevation of cortisol is associated with stress, impaired recovery, and unwanted metabolic effects, while elevated prolactin can disrupt reproductive and endocrine balance. In preclinical models, Ipamorelin showed little to no measurable effect on these hormones at GH-stimulating doses.

This clean profile is thought to stem from the peptide's specific binding characteristics at the GHS-R1a receptor and its relative lack of off-target activity. For researchers and clinicians, the appeal is straightforward: a more predictable response with fewer confounding hormonal variables. GHRP-6 also notably stimulates appetite via ghrelin-like signaling, an effect that is far less pronounced with Ipamorelin.

It should be emphasized that "selective" does not mean "without effect" or "completely safe." Selectivity here refers to a narrower hormonal footprint observed in research, not a guarantee of safety in humans. The long-term consequences of repeated GHS-R1a stimulation in people have not been established in large, controlled clinical trials.

Because Ipamorelin elevates endogenous GH and, indirectly, IGF-1, research interest has focused on outcomes traditionally associated with the GH/IGF-1 axis. It is essential to frame these as areas of investigation rather than proven human benefits, since most data derive from animal models and small studies.

The most studied area is bone and tissue metabolism. Animal research has explored GH secretagogues for their potential influence on bone mineral content and recovery from catabolic states. A study by Andersen and colleagues examined Ipamorelin's effect on bone in glucocorticoid-treated rats, reflecting interest in counteracting the muscle and bone loss caused by steroid therapy.

A second area is gastrointestinal motility. Because the GHS-R1a receptor and ghrelin signaling are involved in gut function, Ipamorelin has been studied for postoperative ileus — a temporary paralysis of the intestine after surgery. Early clinical investigation, including work by Beck et al. (2014), explored whether GHS compounds could accelerate the return of bowel function, though this line of development did not lead to an approved therapy.

In the wider research and fitness community, Ipamorelin is discussed in the context of recovery, body composition, and sleep quality, since GH is naturally released during deep sleep. However, robust, peer-reviewed human evidence for these specific applications remains limited. Readers interested in how peptides are combined for these goals can review our guide to peptide stacking. None of these uses are FDA-approved, and claims of guaranteed body-composition results are not supported by the current literature.

Why Is Ipamorelin Combined With CJC-1295?

One of the most frequently discussed pairings in peptide research is Ipamorelin with CJC-1295. The logic behind the combination is rooted in basic endocrinology: the two compounds act on different receptors and complementary pathways, producing an additive — and according to some research, synergistic — effect on GH release.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and increases the amount of GH the gland is primed to release. Ipamorelin, acting on the separate GHS-R1a (ghrelin) receptor, then triggers the release of that primed hormone. In essence, CJC-1295 increases the size of the GH "pool" while Ipamorelin opens the gate to release it.

This dual-receptor approach mirrors how the body naturally coordinates GH secretion, where GHRH and ghrelin work together. Studies on GHRH and GHS co-administration have shown that the combined GH response can be greater than the sum of each compound given alone. CJC-1295 is also available in two forms — with or without a Drug Affinity Complex (DAC) — which dramatically changes its half-life and dosing frequency; the no-DAC version (sometimes called Mod GRF 1-29) has a much shorter duration suited to pulsatile pairing with Ipamorelin.

Because the two peptides have different durations of action, the pairing is often timed so that both reach the pituitary together. The combination is popular precisely because it leverages two mechanisms while still preserving the body's pulsatile rhythm and feedback control — at least in theory. Readers exploring how such combinations are structured may find our peptide stacking guide helpful. As with Ipamorelin alone, this combination is not approved for human use, and combining peptides may compound rather than reduce risk.

The safety appeal of Ipamorelin rests largely on its selectivity and its preservation of physiological feedback. By relying on the pituitary's own reserve, it carries a lower theoretical risk of the supraphysiological GH levels associated with injected rhGH. That said, no peptide is free of risk, and the human safety database for Ipamorelin is thin.

Reported and theoretical side effects, drawn from research on GHS compounds generally, include the following:

• Injection-site reactions: redness, swelling, or irritation at the subcutaneous administration site.
• Water retention and joint discomfort: classic GH-related effects, generally dose-dependent.
• Headache, flushing, or transient dizziness: sometimes reported shortly after administration.
• Effects on glucose metabolism: GH is a counter-regulatory hormone to insulin, so elevated GH may influence insulin sensitivity and blood glucose, a particular concern for those with or at risk of diabetes.

Because Ipamorelin raises GH and IGF-1, there are also longer-term theoretical concerns shared by all GH-elevating strategies. Chronically elevated IGF-1 has been studied in relation to cellular proliferation, which is why individuals with active or prior cancer are generally cautioned against GH-axis stimulation. These risks have not been quantified for Ipamorelin specifically.

Quality and sourcing introduce additional, often underappreciated, risks. Research-grade peptides are not manufactured to pharmaceutical standards, and contamination, incorrect dosing, or mislabeling are real possibilities. This is one reason the distinction between research use and clinical use is so important. For a fuller discussion of these considerations, see our medical disclaimer. Always consult a healthcare professional before considering any peptide.

How Is Ipamorelin Dosed in Research?

The following information describes dosing ranges that appear in the research and educational literature. It is provided strictly for educational purposes and does not constitute a recommendation or protocol for human use. Ipamorelin is not an approved medication, and self-administration carries real risks.

In research and informal protocols, Ipamorelin is typically administered by subcutaneous injection after reconstitution with bacteriostatic water. Commonly cited ranges fall between 100 and 300 micrograms (mcg) per dose, sometimes administered once to three times daily. The rationale for split dosing is to better mimic the body's natural pulsatile GH rhythm.

Timing is frequently emphasized in the literature. Many protocols suggest administration in a fasted state and/or before sleep, because elevated blood glucose and insulin can blunt GH release, and because the largest natural GH pulse occurs during early deep sleep. Avoiding carbohydrate intake immediately around dosing is a commonly cited practice.

The concept of a physiological ceiling is central to dosing discussions: because Ipamorelin works through the pituitary's own reserve, exceeding a certain dose is thought to yield diminishing returns rather than ever-greater GH output. This is one of the theoretical advantages of secretagogues over direct hormone administration. Even so, more is not better, and higher doses increase the likelihood of side effects without proportional benefit.

What Is the Legal and Regulatory Status of Ipamorelin?

Ipamorelin occupies a regulatory gray area. It has never received marketing approval as a drug from the FDA, the EMA, or other major regulatory agencies, meaning it cannot legally be sold or marketed for the diagnosis, treatment, or prevention of any condition in humans.

In practice, Ipamorelin is sold as a research chemical, labeled "for research use only" and "not for human consumption." This designation places responsibility on the buyer and exempts the product from the manufacturing and purity standards required of approved pharmaceuticals. The legal status of purchasing and possessing such compounds varies considerably from one jurisdiction to another, and some countries treat them more strictly than others.

For competitive athletes, the situation is unambiguous. The World Anti-Doping Agency (WADA) prohibits growth hormone secretagogues, including Ipamorelin, under the S2 category covering peptide hormones, growth factors, and related substances. Their use is banned both in and out of competition, and a positive test carries serious sanctions.

Anyone evaluating Ipamorelin should weigh these legal, regulatory, and quality factors carefully. The absence of approval reflects not just bureaucratic delay but a genuine lack of the large-scale human safety and efficacy data that approval requires. This article is educational and does not endorse use; consult a qualified healthcare professional and verify the laws applicable in your own region before making any decision.